Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Short summary

Lenalidomide maintenance therapy after autologous stem-cell transplantation significantly improved progression-free survival by 18 months (41 vs. 23 months) in multiple myeloma patients compared to placebo, with similar overall survival at 4 years but a higher incidence of second primary cancers.

AI-generated from the title and abstract; the full text is not read.